When Product Training Creates Liability: Risks for Biologics Companies and Their Sales Representatives
News & Posts When Product Training Creates Liability: Risks for Biologics Companies and Their Sales Representatives Product training in the biologics sector poses significant liability
What Insurance Does a Biologics Distributor Need? A Coverage Guide for 2026
News & Posts What Insurance Does a Biologics Distributor Need? A Coverage Guide for 2026 A biologics distributor needs several essential insurance coverages to manage
Is Your Biologics Vendor Actually Insured? How Clinics Should Review a Certificate of Insurance
News & Posts Is Your Biologics Vendor Actually Insured? How Clinics Should Review a Certificate of Insurance Clinics must meticulously evaluate their biologics vendors’ certificates
Cold-Chain, Shipping, and Storage Failures: Who Is Liable When a Biologic Is Compromised?
News & Posts Cold-Chain, Shipping, and Storage Failures: Who Is Liable When a Biologic Is Compromised? Cold-chain failures in the transportation and storage of biologics
Muse Cells Explained: Clearing Up the Confusion Around Stem Cells and Emerging Regenerative Medicine
News & Posts Muse Cells Explained: Clearing Up the Confusion Around Stem Cells and Emerging Regenerative Medicine “Multilineage-differentiating stress-enduring (Muse) cells are a unique type
When Risk Travels Upstream: What Biologics Manufacturers Must Understand About Clinic-Level Exposure
News & Posts When Risk Travels Upstream: What Biologics Manufacturers Must Understand About Clinic-Level Exposure Biologics manufacturers increasingly face liability that originates from clinic-level practices.
Chain of Custody Matters: The Growing Risk of Uncontrolled Biologic Use in Regenerative Medicine
News & Posts Chain of Custody Matters: The Growing Risk of Uncontrolled Biologic Use in Regenerative Medicine The integrity of biologics in regenerative medicine hinges
As Regenerative Medicine Scales Globally, Biologics Manufacturers Face a New Class of Risk
News & Posts As Regenerative Medicine Scales Globally, Biologics Manufacturers Face a New Class of Risk As regenerative medicine expands globally, biologics manufacturers confront unprecedented
The Hidden Downstream Risk Facing U.S. Biologics Manufacturers in Regenerative Medicine
News & Posts The Hidden Downstream Risk Facing U.S. Biologics Manufacturers in Regenerative Medicine U.S. biologics manufacturers in regenerative medicine confront significant downstream risks that
Navigating Insurance For Non-FDA-Approved Therapies: How Integrative And Regenerative Clinics Can Qualify For Coverage
News & Posts Navigating Insurance For Non-FDA-Approved Therapies: How Integrative And Regenerative Clinics Can Qualify For Coverage In the evolving landscape of healthcare, integrative and